The promise of personalized and precision oncology treatment is just starting to emerge with early successes in combination therapies. Although several therapies have been approved, the unmet medical need for cancer patients remains high, with only a minority of patients able to enjoy a durable benefit from the clinical stage or approved immunotherapies.
Biopharma and providers are challenged to implement new precision diagnosis methods that can quickly identify the cellular histology and progression of disease at scale.
They are even more challenged to match precision diagnosis to available clinical studies and therapies at the point in a patient’s journey where a patient, care team, treating oncologist, and a study team can assess what treatment path promises the best outcome. Time is critical, and the very first conversation with a patient is a “must-win” in terms of trust, outlook, and hope.